Guggenheim lowered the firm’s price target on Veracyte (VCYT) to $37 from $45 and keeps a Buy rating on the shares. The firm adjusted its 2025 revenue and test volumes based on recent management commentary, updated its model for the latest 10K release post-earnings and revised its price target to reflect multiple compression in the peer group.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue